Effects of naltrexone treatment for alcohol-related disorders on healthcare costs in an insured population

Alcoholism: Clinical and Experimental Research

Volumn 34, Issue 6, 2010, Pages 1090-1097

  Kranzler, Henry R ^a   Montejano, Leslie B ^b   Stephenson, Judith J ^c   Wang, Shaohung ^c   Gastfriend, David R ^d  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b Outcomes Research   (United States)

^c HEALTHCORE INC   (United States)

^d ALKERMES INC   (United States)

Author keywords

Alcohol Related Disorders; Alcoholism; Healthcare Costs; Naltrexone; Pharmacoeconomics

Indexed keywords

NALTREXONE; NARCOTIC ANTAGONIST;

ADULT; ALCOHOL ABUSE; ALCOHOLISM; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; ALCOHOL-RELATED DISORDERS; CASE CONTROL STUDY; ECONOMICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; ADULT; ALCOHOL-RELATED DISORDERS; CASE-CONTROL STUDIES; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NALTREXONE; NARCOTIC ANTAGONISTS;

EID: 77952908126     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2010.01185.x     Document Type: Article

References (27)

1. Caetano R, Cunradi C (1997) Alcohol dependence: a public health perspective. Addiction 97 : 633 645.
2. Cohen E, Feinn R, Arias A, Kranzler HR (2007) Alcohol treatment utilization: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 86 : 214 221.
3. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J (2003) VA Naltrexone Study Group 42: Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 6 : 566 573.
4. D'Hoore W, Bouckaert A, Tilquin C (1996) Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 49 : 1429 1433.
5. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293 : 1617 1625.
6. Grant BF, Dawson DA, Stinson FS, Chou SP, Dufour MC, Pickering RP (2004) The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend 74 : 223 234.
7. Harris KM, DeVries A, Dimidjian K (2004) Datapoints: Trends in naltrexone use among members of a large private health plan. Psychiatr Serv 55 : 221.
8. Harwood H (2000) Updating Estimates of the Economic Costs of Alcohol Abuse in the United States: Estimates, Update Methods, and Data. Report prepared by The Lewin Group for the National Institute on Alcohol Abuse and Alcoholism. Based on estimates, analyses, and data reported in Harwood, H, Fountain D, Livermore G. The Economic Costs of Alcohol and Drug Abuse in the United States 1992. Report prepared for the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Department of Health and Human Services. NIH Publication No. 98-4327. Rockville, MD: National Institutes of Health, 1998. Available from: http://pubs.niaaa.nih. gov/publications/economic-2000/alcoholcost.PDF.
9. Harwood H, Fountain D, Livermore G (1998) The economic costs of alcohol and drug abuse in the United States 1992. Report prepared for the National Institute on Drug Abuse and the national Institute on Alcohol Abuse and Alcoholism, Nation Institutes of Health, Department of Health and Human Services. National Institute of Health Publication No. 98-4327. Rockville, MD: National Institutes of Health. Available from: http://www.nida.nih.gov/ Economics-Costs/Index.html.
10. Hermos JA, Young MM, Gagnon DR, Fiore LD (2004) Patterns of dispensed disulfiram and naltrexone for alcoholism treatment in a veteran patient population. Alcohol Clin Exp Res 28 : 1229 1235.
11. Holder HD (1998) Cost benefits of substance abuse treatment: an overview of results from alcohol and drug abuse. J Ment Health Policy Econ 1 : 23 29.
12. Holder HD, Blose JO (1992) The reduction of health care costs associated with alcoholism treatment: a 14-year longitudinal study. J Stud Alcohol 53 : 293 302.
13. Kranzler H, Stephenson J, Montejano L, Wang S, Gastfriend D (2008) Persistence with oral naltrexone for alcohol treatment: implications for healthcare utilization. Addiction 103 : 1801 1808.
14. Liang K, Zeger S (1986) Longitudinal data analysis using generalized linear models. Biometrika 73 : 13 22.
15. Mandrekar JN, Mandrekar SJ (2004). An introduction to matching and its application using SAS®, In: SAS Institute Inc. Proceedings of the Twenty-Ninth Annual SAS® Users Group International Conference. SAS Institute Inc., Cary, NC.
16. Mojtabai R, Olfson M, Mechanic D (2002) Perceived need and help-seeking in adults with mood, anxiety, or substance use disorders. Arch Gen Psychiatry 59 : 77 84.
17. O'Farrell TJ, Allen JP, Litten RZ (1995) Disulfiram (antabuse) contracts in treatment of alcoholism. NIDA Res Monogr 150 : 65 91.
18. Parthasarathy S, Weisner C, Hu TW, Moore C (2001) Association of outpatient alcohol and drug treatment with health care utilization and cost: revisiting the offset hypothesis. J Stud Alcohol 62 : 89 97.
19. Pettinati HM, Meyers K, Evans BD, Ruetsch CR, Kaplan FN, Jensen JM, Hadley TR (1999) Inpatient alcohol treatment in a private healthcare setting: which patients benefit and at what cost? Am J Addict 8 : 220 233.
20. Pettinati HM, Volpicelli JR, Pierce JD Jr., O'Brien CP (2000) Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis 19 : 71 83.
21. Putnam KG, Buist DS, Fishman P, Andrade SE, Boles M, Chase GA, Goodman MJ, Gurwitz JH, Platt R, Raebel MA, Arnold Chan K (2002) Chronic disease score as a predictor of hospitalization. Epidemiology 13 : 340 346.
22. Rabinowitz J, Gross R, Feldman D (1999) Correlates of a perceived need for mental health assistance and differences between those who do and do not seek help. Soc Psychiatry Psychiatr Epidemiol 34 : 141 146.
23. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK (1993) The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 50 : 85 94.
24. Starosta AN, Leeman RF, Volpicelli JR (2006) The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. J Psychiatr Pract 12 : 80 89.
25. Valderas JM, Starfield MDB, Sibbald B, Salisbury C, Roland M (2009) Defining comorbidity: Implications for understanding health and health services. Ann Fam Med 7 : 357 363.
26. Von Korff M, Wagner E, Saunders K (1992) A chronic disease score from automated pharmacy data. J Clin Epidemiol 45 : 197 203.
27. Wu L, Ringwalt CL, Williams CE (2003) Use of substance abuse treatment services by persons with mental health and substance use problems. Psychiatr Serv 54 : 363 369.